Shumin Ouyang
Overview
Explore the profile of Shumin Ouyang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lou L, Peng K, Ouyang S, Ding W, Mo J, Yan J, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):6.
PMID: 39762921
Background: Metastasis is the primary cause of mortality in small cell lung cancer (SCLC), with the liver being a predominant site for distal metastasis. Despite this clinical significance, mechanisms underlying...
2.
Ouyang S, Shi S, Ding W, Ge Y, Su Y, Mo J, et al.
Adv Sci (Weinh)
. 2024 Oct;
11(46):e2407967.
PMID: 39422674
Uveal melanoma (UM), the predominant primary ocular malignancy, often progresses to liver metastasis with limited therapeutic options. The interplay of the tumor microenvironment, encompassing secreted soluble factors, plays a crucial...
3.
Lu J, Li J, Lin Z, Li H, Lou L, Ding W, et al.
Cancer Lett
. 2023 May;
564:216205.
PMID: 37146936
Cross-talk between the tumor microenvironment (TME) and cancer cells plays an important role in acquired drug resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The role of tumor-associated...
4.
Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X, et al.
Cancer Res
. 2023 Apr;
83(13):2187-2207.
PMID: 37061993
Significance: IGF2BP3 stabilizes COX6B2 to increase oxidative phosphorylation and to drive resistance to EGFR inhibitors in lung cancer, which provides a therapeutic strategy to overcome acquired resistance by targeting metabolic...
5.
Mo J, Deng L, Peng K, Ouyang S, Ding W, Lou L, et al.
J Hematol Oncol
. 2023 Feb;
16(1):15.
PMID: 36849939
The acute myeloid leukemia (AML) patients obtain limited benefits from current immune checkpoint blockades (ICBs), although immunotherapy have achieved encouraging success in numerous cancers. Here, we found that V-domain Ig...
6.
Li H, Ouyang S, Zhang Y, Peng K, Fang W, Liu Z, et al.
Eur J Med Chem
. 2022 Oct;
244:114858.
PMID: 36283181
STAT3 is a promising therapeutic target for the treatment of gastric cancer, which is one of the most common solid tumors worldwide. In the previous works, we discovered a series...
7.
Liao M, Chen L, Lu J, Liang G, Yao Y, Ouyang S, et al.
Mediators Inflamm
. 2022 Oct;
2022:2689918.
PMID: 36193415
Objective: To investigate the mechanism of Connexin 37 (Cx37) and Kv1.3 pathways in atherosclerosis (AS). Methods: ApoE mice were given a high-fat diet to establish atherosclerosis (AS) model, and macrophages...
8.
Deng L, Mo J, Zhang Y, Peng K, Li H, Ouyang S, et al.
J Med Chem
. 2022 Sep;
65(19):13094-13111.
PMID: 36170649
SH2 domains have been recognized as promising targets for various human diseases. However, targeting SH2 domains with phosphopeptides or small-molecule inhibitors derived from bioisosteres of the phosphate group is still...
9.
Ge Y, Deng J, Zhu J, Liu L, Ouyang S, Song Z, et al.
Acta Pharm Sin B
. 2022 Aug;
12(8):3326-3340.
PMID: 35967274
Constitutively activated G proteins caused by specific mutations mediate the development of multiple malignancies. The mutated Gq/11 are perceived as oncogenic drivers in the vast majority of uveal melanoma (UM)...
10.
Ouyang S, Zhang Q, Lou L, Zhu K, Li Z, Liu P, et al.
Front Pharmacol
. 2022 May;
13:871560.
PMID: 35571098
Reprogramming of cellular energy metabolism is considered an emerging feature of cancer. Mitochondrial metabolism plays a crucial role in cancer cell proliferation, survival, and metastasis. As a major mitochondrial NAD-dependent...